Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab for Gout Flares in Patients Intolerant to NSAIDs/Colchicine
NCT01362608Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jun 2011
- Primary completion
- May 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of canakinumab in gouty arthritis, sponsored by Novartis. Started Jun 2011; status: terminated.
02
Drugs
canakinumab
03
Conditions
gouty arthritis
Beyond the preview
Go deeper on NCT01362608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01362608.